Brilliant Violet 421™ anti-mouse CD304 (Neuropilin-1)

Antibodies Single
Sony
3E12
Flow Cytometry
Rat IgG2a, κ
Mouse
Extracellular region of mouse CD304
125 µl
1326045
$208.00

Description

CD304, also known as neuropilin-1, is a 140 kD type I transmembrane protein. Its extracellular region contains two CUB, two FV/FVIII, and one MAM domain. It is expressed by natural regulatory T cells (nTreg), a subset of invariant natural killer T cells (iNKT), endothelial cells, and neurons. Neuropilin-1 stabilizes the interaction between Tregs and dendritic cells, contributes to the recruitment of tumor-infiltrating Tregs in response to tumor-derived VEGF, and influences the process of angiogenesis and axon guidance. The ligands of CD304 are VEGF165 and semaphorin-3A.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

References

1. Blankenhaus B, et al. 2014. PLoS Pathog. 10:1003913. PubMed
2. Verhagen J and Wraith DC. 2014. J. Immunol. Methods. S0022. (FC) PubMed
3. Verhagen J, et al. 2014. PLoS One. 9e:108023. (FC) PubMed